Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMDW NASDAQ:BBLGW OTCMKTS:CLLKF OTCMKTS:MEDGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDWAinos$0.45-2.2%$0.21$0.03▼$0.95N/AN/A14,325 shs1,352 shsBBLGWBone Biologics$10.79-28.1%$14.20$3.00▼$95.04N/AN/A1,843 shs400 shsCLLKFBICO Group AB (publ)C$2.84+1.2%C$3.67C$2.59▼C$5.60N/AN/A1,785 shs100 shsMEDGFMedacta Group$83.91$83.91$83.91▼$86.33N/AN/A200 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDWAinos-4.15%-41.01%+181.75%+228.64%+557.29%BBLGWBone Biologics0.00%0.00%-28.07%-20.07%-82.17%CLLKFBICO Group AB (publ)+1.23%-24.27%-20.00%-22.51%-32.38%MEDGFMedacta Group0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDWAinosN/AN/AN/AN/AN/AN/AN/AN/ABBLGWBone BiologicsN/AN/AN/AN/AN/AN/AN/AN/ACLLKFBICO Group AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AMEDGFMedacta GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDWAinos 0.00N/AN/AN/ABBLGWBone Biologics 0.00N/AN/AN/ACLLKFBICO Group AB (publ) 0.00N/AN/AN/AMEDGFMedacta Group 2.50Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest MEDGF, AIMDW, CLLKF, and BBLGW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025MEDGFMedacta GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDWAinos$110.87KN/AN/AN/AN/AN/ABBLGWBone BiologicsN/AN/AN/AN/AN/AN/ACLLKFBICO Group AB (publ)N/AN/AN/AN/AN/AN/AMEDGFMedacta GroupN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDWAinosN/AN/A0.00∞N/AN/AN/AN/AN/ABBLGWBone BiologicsN/AN/A0.00∞N/AN/AN/AN/AN/ACLLKFBICO Group AB (publ)N/AN/A0.00∞N/AN/AN/AN/AN/AMEDGFMedacta GroupN/AN/A0.00∞N/AN/AN/AN/A9/8/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDWAinosN/AN/AN/AN/AN/ABBLGWBone BiologicsN/AN/AN/AN/AN/ACLLKFBICO Group AB (publ)N/AN/AN/AN/AN/AMEDGFMedacta GroupN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDWAinosN/ABBLGWBone BiologicsN/ACLLKFBICO Group AB (publ)N/AMEDGFMedacta GroupN/AInsider OwnershipCompanyInsider OwnershipAIMDWAinosN/ABBLGWBone BiologicsN/ACLLKFBICO Group AB (publ)N/AMEDGFMedacta GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDWAinos40N/AN/ANot OptionableBBLGWBone Biologics2N/AN/ANot OptionableCLLKFBICO Group AB (publ)880N/AN/ANot OptionableMEDGFMedacta Group1,826N/AN/ANot OptionableMEDGF, AIMDW, CLLKF, and BBLGW HeadlinesRecent News About These CompaniesThe recent 3.5% gain must have brightened CEO Francesco Siccardi's week, Medacta Group SA's (VTX:MOVE) most bullish insiderAugust 13, 2025 | finance.yahoo.comMedacta Group SA Reports Strong H1 2025 Revenue Growth and Upgrades GuidanceJuly 31, 2025 | tipranks.comMedacta Group SA (MEDGF) - Yahoo FinanceJuly 5, 2025 | au.finance.yahoo.comEstimating The Fair Value Of Medacta Group SA (VTX:MOVE)May 9, 2025 | finance.yahoo.comMedacta Group SA Approves Board Proposals and Financial Strategies at AGMMay 7, 2025 | tipranks.comMedacta publishes 2025 Annual General Meeting invitationApril 8, 2025 | markets.businessinsider.comMedacta Group SA (VTX:MOVE) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This YearMarch 28, 2025 | finance.yahoo.comMedacta Group price target raised to CHF 146 from CHF 136 at Morgan StanleyMarch 27, 2025 | markets.businessinsider.comMedacta Dramatically Expands Sports Med FranchiseMarch 26, 2025 | ryortho.comRMedacta Group SA (XSWX:MOVE) Full Year 2024 Earnings Call Highlights: Record Growth and ...March 26, 2025 | gurufocus.comFull Year 2024 Medacta Group SA Earnings Call TranscriptMarch 25, 2025 | gurufocus.comMedacta Group SA Achieves Robust Growth in 2024 with Innovative Orthopedic SolutionsMarch 25, 2025 | tipranks.comMedacta Group SA: Strong Financial Performance and Growth Potential Justify Buy RatingMarch 25, 2025 | tipranks.comWhy Medacta Group SA (VTX:MOVE) Could Be Worth WatchingMarch 25, 2025 | finance.yahoo.comMedacta Group SA: Medacta Group SA reports an excellent performance in 2024 with an adjusted EBITDA margin1 in constant currency of 28.0%March 25, 2025 | markets.businessinsider.comMedacta acquires sports medicine companyMarch 7, 2025 | beckersspine.comBAnika Therapeutics Completes Sale of Parcus Medical to Medacta Group SAMarch 7, 2025 | quiverquant.comQMEDGF Medacta Group SAFebruary 26, 2025 | seekingalpha.comMedacta Group price target raised to CHF 160 from CHF 150 at BerenbergFebruary 13, 2025 | markets.businessinsider.comMedacta Group price target raised to CHF 136 from CHF 135 at Morgan StanleyFebruary 6, 2025 | markets.businessinsider.comMedia Sentiment Over TimeMEDGF, AIMDW, CLLKF, and BBLGW Company DescriptionsAinos NASDAQ:AIMDW$0.45 -0.01 (-2.17%) As of 10:50 AM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Bone Biologics NASDAQ:BBLGW$10.79 -4.21 (-28.07%) As of 08/20/2025Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.BICO Group AB (publ) OTCMKTS:CLLKFC$2.84 +0.03 (+1.23%) As of 08/20/2025 10:51 AM EasternBICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing. The Biosciences segment provides instruments that enable the handling of cells and rare samples, and rapid transfer of liquids and reagents, as well as downstream analysis platforms. The Bioautomation segment offers end-to-end products and services in precision dispensing, advanced sample preparation, multiplex analysis and assay miniaturization, diagnostic and medical device manufacturing for life science and diagnostic industries. It primarily serves medical, pharmaceutical, and cosmetic industries. The company offers its products through sales organizations, as well as through an extensive distributor network. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was incorporated in 2016 and is headquartered in Gothenburg, Sweden.Medacta Group OTCMKTS:MEDGF$83.91 0.00 (0.00%) As of 08/15/2025Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine procedures. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access